Target intelligence / Profile preview

DNA polymerase gamma, catalytic subunit (human) (POLG)

Target
POLG
Molecular classification
Enzyme, DNA polymerase, Transferase, Mitochondrial protein, DNA replication and repair protein
01

Overview

DNA polymerase gamma is the sole DNA polymerase responsible for replication and repair of mitochondrial DNA in human cells. It functions as a heterotrimeric holoenzyme composed of a single catalytic subunit (encoded by the POLG gene) and a dimer of accessory subunits; the catalytic subunit has both polymerase (replicative) and 3’-5’ exonuclease (proofreading) activities. Proper function of this enzyme is essential for maintenance of mitochondrial genome stability, energy metabolism, and cellular homeostasis. Mutations in POLG or inhibition by certain antiviral drugs (notably NRTIs for HIV) can result in mitochondrial DNA depletion or multiple deletions, contributing to a range of mitochondrial diseases with neurological, hepatic, muscular, or gastrointestinal manifestations. This enzyme is therefore both a key biomolecule for normal mitochondrial function and a clinically important drug target and toxicity mediator.

Other names
DNA polymerase γpolymerase gammaPol γPOLGmitochondrial DNA polymeraseDNA polymerase subunit gammapolGDNA polymerase gamma catalytic subunitmitochondrial DNA polymerase gamma
02

Mechanism of action

Inhibition of polymerase activity via incorporation of nucleoside analogs, Competitive inhibition, Chain termination during replication

03

Biological functions

Mitochondrial DNA replicationMitochondrial DNA repairGenome maintenanceProofreading/error correctionEnergy metabolism supportCell cycle control
04

Disease associations

Mitochondrial diseaseNeurodegenerative diseaseProgressive external ophthalmoplegiaAlpers-Huttenlocher syndromeMitochondrial neurogastrointestinal encephalopathySensory ataxic neuropathy dysarthria and ophthalmoparesisDrug-induced mitochondrial toxicity
05

Safety considerations

Mitochondrial toxicity (drug-induced)Mutation-associated organ dysfunction (neurological, hepatic, gastrointestinal)Risk of lactic acidosis with NRTIsAccumulation of mitochondrial DNA mutations or deletionsDisease phenotypes from loss of function
06

Interacting drugs

Nucleoside reverse transcriptase inhibitors (NRTIs; e.g., zidovudine, stavudine, didanosine, lamivudine, emtricitabine, abacavir, tenofovir)
07

Biomarkers

POLG mutation status (genetic testing)Mitochondrial DNA copy numberSerum or tissue lactic acid levels (indirect)

Beyond the preview

Go deeper on DNA polymerase gamma, catalytic subunit (human) (POLG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA polymerase gamma, catalytic subunit (human) (POLG).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call